Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}} Now: 1770728770712 Cache Key: cqdTagPageBySlug:disease-modifying-therapy-dmt fetchCache[cqdTagPageBySlug:disease-modifying-therapy-dmt].expirationTime: falsey fetchCache[cqdTagPageBySlug:disease-modifying-therapy-dmt]. seconds remaining: falsey All fetchCache expiration times: -- Key: cqdNotFoundPage, seconds remaining: 4177 -- Key: cqdTagPageBySlug:knee-arthroscopy, seconds remaining: -7097 -- Key: cqdPostsByTag:cqd-migrated-tag-25126,1,10, seconds remaining: -7018 -- Key: cqdTagPageBySlug:nursing-webchats, seconds remaining: -6646 -- Key: cqdPostsByTag:cqd-migrated-tag-17352,1,10, seconds remaining: -6560 -- Key: cqdTagPageBySlug:painkillers, seconds remaining: -3940 -- Key: cqdPostsByTag:cqd-migrated-tag-2921,1,10, seconds remaining: -3863 -- Key: cqdTagPageBySlug:nursing-luminaries, seconds remaining: -3521 -- Key: cqdPostsByTag:cqd-migrated-tag-24988,1,10, seconds remaining: -3445 -- Key: cqdTagPageBySlug:arthrodesis, seconds remaining: -333 -- Key: cqdPostsByTag:cqd-migrated-tag-4540,1,10, seconds remaining: -250 -- Key: cqdTagPageBySlug:asco19, seconds remaining: 4177 -- Key: cqdPostsByTag:cqd-migrated-tag-20730,1,10, seconds remaining: 4253 -- Key: cqdTagPageBySlug:mycobacterium-avium-complex-mac, seconds remaining: 5045 -- Key: cqdPostsByTag:cqd-migrated-tag-23553,1,10, seconds remaining: 5113 -- Key: cqdTagPageBySlug:lars-scensson, seconds remaining: 9132 -- Key: cqdPostsByTag:cqd-migrated-tag-17396,1,10, seconds remaining: 9225 conditions: -- false, -- NA, -- NA, -- NA -- false Cache miss for key cqdTagPageBySlug:disease-modifying-therapy-dmt - retrieving from Sanity CCCache.dataFetchCount: 3050 Cache cleanup seconds remaining: 12903
Advertisement
Advertisement
Tag: disease-modifying therapy (DMT)
Rebound risk is shaped by patient characteristics and mechanism of action of current DMT
First-of-kind prediction model demonstrates high consistency across internal and external validation
Real-world study also finds no significant rise in ocrelizumab-related risk with advanced age
The disease is not a barrier to pregnancy, but risks from disease-modifying therapies must be managed
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy
$1.1M award expands follow-up to six years with focus on clinical endpoints
Relapse rates were lower with oral or infusion therapy after initial injectable DMT
Observational studies comparing disease-modifying therapies can help guide clinical decisions
Unlikely to be severe, infections are associated with anti-CD20 therapies and fingolimod
Observational study suggests age may be a better guide than disease stability
Rendered: Tue Feb 10 2026 13:06:10 GMT+0000 (Coordinated Universal Time)
9500 Euclid Avenue, Cleveland, Ohio 44195 |
800.223.2273 | ©
2026 Cleveland Clinic. All Rights Reserved.
Search
